Phytotherapy for treatment of benign prostatic hyperplasia: Case not proven

Urology

Volumn 53, Issue 3, 1999, Pages 462-464

  Fitzpatrick, John M ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

PLANT EXTRACT; PYGEUM AFRICANUM EXTRACT; URTICA DIOICA EXTRACT;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG PREFERENCE; EDITORIAL; EVIDENCE BASED MEDICINE; HUMAN; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SABAL;

HUMANS; MALE; PHYTOTHERAPY; PROSTATIC HYPERPLASIA;

EID: 0033104387     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00648-7     Document Type: Editorial

References (15)

1. Rhodes L, Primka RL, Berman C, et al: Comparison of finasteride (Proscar®), a 5-alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5-alpha reductase inhibition. Prostate 22: 43-51, 1993.
2. Di Silverio F, Sciarra A, D'Eramo G, et al: Response to tissue androgen and epidermal growth factor concentrations to the administration of finasteride, flutamide and Seronoa repens in patients with BPH (abstract). Eur Urol 30(suppl 2): 317, 1996.
3. Bayne CW, Grant ES, Chapman K, et al: Characterisation of a new CD-culture model for BPH which expresses 5-alpha reductase types I and II; the effects of Permixon® on DHT formation (abstract). J Urol 157(suppl): 755, 1997.
4. Di Silverio F, D'Eramo G, Lubrano C, et al: Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hyperplasia patients. Eur Urol 21: 309-314, 1992.
5. Paubert-Braquet M, Raynaud JP, Braquet G, et al: Permixon® (lipid sterolic extract of Serenoa repens) and some of its components inhibit B-FGF- and EGF-induced proliferation of human prostate organotypic cell lines (abstract). J Urol 157(suppl): 541, 1997.
6. Paubert-Braquet M, Mombsisse JC, Boichot-Lagente JC, et al: Pygeum africanum extract inhibits BFGF and EGF induced proliferation of 3T3 fibroblasts. Biomed Pharmacother 48: 13-17, 1994.
7. Levin RM, Riffaud JP, Bellamy F, et al: Effects of Tadenan® pre-treatment on bladder physiology and biochemistry following partial outlet obstruction. J Urol 156: 2084-2088, 1996.
8. Levin RM, Riffaud JP, Bellamy F, et al: Protective effect of Tadenan® on bladder function secondary to partial outlet obstruction. J Urol 155: 1466-1470, 1996.
9. Jäger W, Eisler B, and Koch HP: Pharmacokinetics and bioavailability of beta-sitosterol in rats: A comparison of three new dosage forms. Pharm Sci Commun 4: 21-27, 1993.
10. Ritschel WA, Kastner U, Hussain AS, et al: Pharmacokinetics and bioavailability of beta-sisosterol in the beagle dog. Arzheim-Forsch 40: 463-468, 1990.
11. Fitzpatrick JM, and Lynch TH: Phytotherapeutic agents in the management of symptomatic benign prostatic hyperplasia. Urol Clin North Am 22: 407-412, 1995.
12. Dreikorn K, Borkowski A, Braeckman J, et al: Other medical therapies, in Denis L, Griffiths K, Khoury S, et al (Eds): Proceedings of the Fourth International Consultation on Benign Prostatic Hyperplasia (BPH). Plymouth, United Kingdom, Health Publication Ltd, pp 633-659, 1998.
13. Berges RR, Windeler J, Trampisch H, et al: Randomised placebo-controlled double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia (Beta-Sitosterol Study Group). Lancet 345: 1529-1532, 1995.
14. Grasso M, Montessano A, Buonaguidi A, et al: Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp Urol 48: 97-103, 1995.
15. Carraro J-C, Raynaud J-P, Koch G, et al: Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostatic hyperplasia: A randomized international study of 1,098 patients. Prostate 29: 231-240, 1996.